HuGE Literature Finder
Records
1
-
4
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022 Jun . Tashakori Mehrnoosh, Khoury Joseph D, Routbort Mark J, Patel Keyur P, Wang Sa A, Ok Chi Young, El-Hussein Siba, Kanagal-Shamanna Rashmi, Luthra Rajyalakshmi, Hu Shimin, Lin Pei, Pemmaraju Naveen, Bose Prithviraj, Verstovsek Srdan, Bueso-Ramos Carlos E, Medeiros L Jeffrey, Loghavi San |
Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Molecular biology reports 2014 Oct 41 (10): 6737-42. Cetin Güven, Ozkan Tuba, Turgut Seda, Ali Cikrikcioglu M, Cem Ar M, Ayer Mesut, Unlu Ayhan, Celik Sevda Rabia, Sekin Yahya, Karatoprak Cuma |
Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PloS one 2013 8 (2): e57856. Zhou Juan, Ye Yuanxin, Zeng Shugen, Zhou Yi, Mao Zhigang, Song Xingbo, Ying Binwu, Lu Xiaojun, Jiang Hong, Wang Lanl |
JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. Journal of clinical pathology 2009 Sep 62 (9): 798-801. Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 01, 2023
- Content source: